Ilya M. Itkin
Research Subjects
Ilya M. Itkin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rashida V. Orlova
St. Petersburg City Clinical Oncology Dispensary; St. Petersburg State University
4 shared publications - Ivan A. Gerk
St. Petersburg City Clinical Oncology Dispensary
3 shared publications И. М. Иткин
Городской клинический онкологический диспансер
3 shared publicationsР. В. Орлова
Городской клинический онкологический диспансер; Санкт-Петербургский государственный университет
3 shared publications- Inna V. Avramenko
St. Petersburg City Clinical Oncology Dispensary
2 shared publications - Natalia V. Zhukova
City Clinical Oncology Dispensary
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 7-19
Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients
The development of immune checkpoint inhibitors (ICIs) has led to significant changes in the treatment strategies for malignant tumors. Results from numerous randomized trials of this class of drugs, alongside their widespread adoption in clinical practice, have demonstrated superior therapeutic efficacy in patients with both locally advanced and disseminated disease. However, the use of ICIs is associated with a range of adverse effects resulting from the strong induction of the patient’s immune response. Unlike other forms of anticancer drug therapy (such as chemotherapy or targeted therapy), the side effects associated with immune checkpoint therapy (ICT) are unpredictable and manifest across various organs and body systems as signs of immune-mediated tissue inflammation. Currently, there are no known predictive factors for the timing, type, or severity of immune-related adverse events associated with ICT. The use of immune checkpoint therapy (ICT) in cancer patients can lead to various disorders, including those affecting the endocrine system. The most common of these are thyroiditis, hypopituitarism, and adrenal insufficiency. However, the literature indicates that type 1 diabetes is also an immune-related complication of ICT. The progression of insulin deficiency in ICT-associated type 1 diabetes occurs more rapidly than in conventional type 1 diabetes. The incidence of type 1 diabetes associated with the use of immune checkpoint inhibitors (ICIs) in cancer patients ranges from 0.3% to 3.5% (1). Immune-related diabetes (irDM) presents with diabetic ketoacidosis or ketosis, typically developing within two weeks of the onset of clinical symptoms of hyperglycemia, such as dry mouth, polydipsia, and polyuria. These symptoms necessitate urgent diagnosis and timely insulin therapy, as endogenous insulin secretion declines within 2–3 weeks of the initial clinical manifestations of diabetes.Furthermore, it has been shown that the level of positive autoantibodies associated with pancreatic islet activity ranges from 5 to 50 MU, while the level of exocrine pancreatic enzymes is only slightly elevated. In this review, we describe the clinical features of type 1 diabetes associated with ICT and present a case from our clinical practice.
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 7-19
Open AccessType 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients
The development of immune checkpoint inhibitors (ICIs) has led to significant changes in the treatment strategies for malignant tumors. Results from numerous randomized trials of this class of drugs, alongside their widespread adoption in clinical practice, have demonstrated superior therapeutic efficacy in patients with both locally advanced and disseminated disease. However, the use of ICIs is associated with a range of adverse effects resulting from the strong induction of the patient’s immune response. Unlike other forms of anticancer drug therapy (such as chemotherapy or targeted therapy), the side effects associated with immune checkpoint therapy (ICT) are unpredictable and manifest across various organs and body systems as signs of immune-mediated tissue inflammation. Currently, there are no known predictive factors for the timing, type, or severity of immune-related adverse events associated with ICT. The use of immune checkpoint therapy (ICT) in cancer patients can lead to various disorders, including those affecting the endocrine system. The most common of these are thyroiditis, hypopituitarism, and adrenal insufficiency. However, the literature indicates that type 1 diabetes is also an immune-related complication of ICT. The progression of insulin deficiency in ICT-associated type 1 diabetes occurs more rapidly than in conventional type 1 diabetes. The incidence of type 1 diabetes associated with the use of immune checkpoint inhibitors (ICIs) in cancer patients ranges from 0.3% to 3.5% (1). Immune-related diabetes (irDM) presents with diabetic ketoacidosis or ketosis, typically developing within two weeks of the onset of clinical symptoms of hyperglycemia, such as dry mouth, polydipsia, and polyuria. These symptoms necessitate urgent diagnosis and timely insulin therapy, as endogenous insulin secretion declines within 2–3 weeks of the initial clinical manifestations of diabetes.Furthermore, it has been shown that the level of positive autoantibodies associated with pancreatic islet activity ranges from 5 to 50 MU, while the level of exocrine pancreatic enzymes is only slightly elevated. In this review, we describe the clinical features of type 1 diabetes associated with ICT and present a case from our clinical practice.
- Open Access
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 21-39
Immune-mediated hepatitis. A literature review
Aim. Immune checkpoint inhibitors (ICIs) have transformed the standards of systemic therapy across a broad range of malignancies; however, the expansion of their indications has inevitably been accompanied by a rise in immunerelated adverse events. The aim of this review is to summarise current understanding of the pathogenesis, clinical presentation, incidence, differential diagnosis and management of immune-mediated hepatitis associated with immune checkpoint inhibitor therapy, comparing the approaches adopted by international and Russian professional societies.Methods. Publications were searched in PubMed/MEDLINE and eLIBRARY, as well as on the official websites of the professional societies ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), RUSSCO (Russian Society of Clinical Oncology) and NCCN (National Comprehensive Cancer Network), and of regulatory agencies (FDA Food and Drug Administration). Current clinical guidelines, official prescribing information, systematic reviews, meta-analyses, randomised trials and real-world data were included. Results. The liver ranks third among the organs affected, after the skin and the gastrointestinal tract. According to the integrated safety databases of regulatory agencies, the incidence of immune-mediated hepatitis was 0.7% for pembrolizumab, 1.8% for nivolumab and atezolizumab, 2.8% for durvalumab, and 7.0 to 15.0% for nivolumab combined with ipilimumab, depending on the dose ratio. PD-1 inhibitors were associated with more frequent transaminase elevations than PD-L1 inhibitors. Management is based on stepwise immunosuppression; mycophenolate mofetil is the second-line agent, whereas infliximab is not used in hepatic involvement.Conclusion. Immune-mediated hepatitis requires differential diagnosis, since a substantial proportion of liver test elevations is due to alternative causes. The extent of immunosuppression should be matched to the clinical severity of the condition rather than to the formal CTCAE grade alone.
- 12 October 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 21-39
Open AccessImmune-mediated hepatitis. A literature review
Aim. Immune checkpoint inhibitors (ICIs) have transformed the standards of systemic therapy across a broad range of malignancies; however, the expansion of their indications has inevitably been accompanied by a rise in immunerelated adverse events. The aim of this review is to summarise current understanding of the pathogenesis, clinical presentation, incidence, differential diagnosis and management of immune-mediated hepatitis associated with immune checkpoint inhibitor therapy, comparing the approaches adopted by international and Russian professional societies.Methods. Publications were searched in PubMed/MEDLINE and eLIBRARY, as well as on the official websites of the professional societies ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), RUSSCO (Russian Society of Clinical Oncology) and NCCN (National Comprehensive Cancer Network), and of regulatory agencies (FDA Food and Drug Administration). Current clinical guidelines, official prescribing information, systematic reviews, meta-analyses, randomised trials and real-world data were included. Results. The liver ranks third among the organs affected, after the skin and the gastrointestinal tract. According to the integrated safety databases of regulatory agencies, the incidence of immune-mediated hepatitis was 0.7% for pembrolizumab, 1.8% for nivolumab and atezolizumab, 2.8% for durvalumab, and 7.0 to 15.0% for nivolumab combined with ipilimumab, depending on the dose ratio. PD-1 inhibitors were associated with more frequent transaminase elevations than PD-L1 inhibitors. Management is based on stepwise immunosuppression; mycophenolate mofetil is the second-line agent, whereas infliximab is not used in hepatic involvement.Conclusion. Immune-mediated hepatitis requires differential diagnosis, since a substantial proportion of liver test elevations is due to alternative causes. The extent of immunosuppression should be matched to the clinical severity of the condition rather than to the formal CTCAE grade alone.
- Open Access
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 8-16
The first domestic combination of nurulimab + prolgolimab: from clinical development and economic analysis to real-world use in disseminated melanoma
Immunotherapy with immune checkpoint inhibitors has dramatically shifted the prognosis for outcomes of melanoma treatment. However, enhancing the efficacy of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 while reducing immune-mediated toxicity remains a clinically significant challenge. This article presents a systematic review of data on the first homegrown fixed-dose combination of dual immune checkpoint inhibitors: anti-CTLA-4 + anti-PD-1 (Nurulimab) + Prolgolimab (Nurdati, BCD-217). We searched articles in the PubMed/MEDLINE, eLIBRARY.ru, ClinicalTrials.gov , Cochrane Library databases, and specialized oncology congress records, using the following keywords in different combinations: unresectable/metastatic melanoma, immunotherapy, checkpoint inhibitors, nurulimab, prolgolimab, Nurdati. A total of 146 articles and information sources were identified at the first stage. After removing duplicates and materials irrelevant to the review topic, 118 records were selected for screening, of which 54 were included in the qualitative analysis. The final review included articles and records covering the molecular and pharmacological properties of nurulimab and prolgolimab, the results of the BCD-217 clinical development, comparative efficacy and safety data, and a cost-effectiveness analysis. The excluded articles got the following reasons in favour of exclusion: inappropriateness, lack of clinical data, duplicate results, and limited access to the full text. In the randomized phase III OCTAVA study, the combination of nurulimab plus prolgolimab demonstrated significantly superior efficacy over prolgolimab monotherapy in terms of median progression-free survival (PFS) with comparable cumulative incidence rates of grade 3–4 AEs. Nurdati is a homegrown innovative medicine that is based on a low-dose CTLA-4 blockade and standard anti-PD-1 therapy, demonstrating durable disease control in a patient with BRAF-wild-type acral melanoma in the presented clinical case.
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 8-16
Open AccessThe first domestic combination of nurulimab + prolgolimab: from clinical development and economic analysis to real-world use in disseminated melanoma
Immunotherapy with immune checkpoint inhibitors has dramatically shifted the prognosis for outcomes of melanoma treatment. However, enhancing the efficacy of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 while reducing immune-mediated toxicity remains a clinically significant challenge. This article presents a systematic review of data on the first homegrown fixed-dose combination of dual immune checkpoint inhibitors: anti-CTLA-4 + anti-PD-1 (Nurulimab) + Prolgolimab (Nurdati, BCD-217). We searched articles in the PubMed/MEDLINE, eLIBRARY.ru, ClinicalTrials.gov , Cochrane Library databases, and specialized oncology congress records, using the following keywords in different combinations: unresectable/metastatic melanoma, immunotherapy, checkpoint inhibitors, nurulimab, prolgolimab, Nurdati. A total of 146 articles and information sources were identified at the first stage. After removing duplicates and materials irrelevant to the review topic, 118 records were selected for screening, of which 54 were included in the qualitative analysis. The final review included articles and records covering the molecular and pharmacological properties of nurulimab and prolgolimab, the results of the BCD-217 clinical development, comparative efficacy and safety data, and a cost-effectiveness analysis. The excluded articles got the following reasons in favour of exclusion: inappropriateness, lack of clinical data, duplicate results, and limited access to the full text. In the randomized phase III OCTAVA study, the combination of nurulimab plus prolgolimab demonstrated significantly superior efficacy over prolgolimab monotherapy in terms of median progression-free survival (PFS) with comparable cumulative incidence rates of grade 3–4 AEs. Nurdati is a homegrown innovative medicine that is based on a low-dose CTLA-4 blockade and standard anti-PD-1 therapy, demonstrating durable disease control in a patient with BRAF-wild-type acral melanoma in the presented clinical case.
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
Clinical case of a giant sarcomatoid carcinoma of the skin arising in the postauricular area
Sarcomatoid carcinoma of the skin is a rare and aggressive variant of cutaneous squamous cell carcinoma characterized by poor differentiation. Due to the limited number of reported cases, there are no standardized approaches to management, making individual case reports particularly valuable. We describe a young patient presenting with a rapidly enlarging giant sarcomatoid carcinoma of the postauricular region with ulceration and bleeding. A combinedmodality treatment, including surgery and chemoimmunotherapy, resulted in complete clinical and radiological disease control, with no evidence of recurrence at follow-up.
- 28 January 2026
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 3 (3)
Clinical case of a giant sarcomatoid carcinoma of the skin arising in the postauricular area
Sarcomatoid carcinoma of the skin is a rare and aggressive variant of cutaneous squamous cell carcinoma characterized by poor differentiation. Due to the limited number of reported cases, there are no standardized approaches to management, making individual case reports particularly valuable. We describe a young patient presenting with a rapidly enlarging giant sarcomatoid carcinoma of the postauricular region with ulceration and bleeding. A combinedmodality treatment, including surgery and chemoimmunotherapy, resulted in complete clinical and radiological disease control, with no evidence of recurrence at follow-up.